Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis

doi:10.3748/wjg.v26.i2.246

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8454)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

523

WORD

201

HTML

4547

Figures (1-5)

341

Tables (1-4)

455

Sum=6067

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

850

Download

1537

Sum=2387

Jan 14, 2020 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. Jan 14, 2020; 26(2): 246-265
Published online Jan 14, 2020. doi: 10.3748/wjg.v26.i2.246

Table 4 Summary of finding table based on a hypothetical scenario[38] of applying glycoprotein 2 antibodies tests on a cohort of 10000 patients

Analysis	Diagnostic cut-off (U/dL)	TP	(Range)	FP	(Range)	TN	(Range)	FN	(Range)
CD vs All symptomatic patients (IgG)	Mixed	9	(6-21)	698		9270		23	(21-26)
	20	7	(5-10)	698	(498-897)	9270	(9071-9470)	25	(22-27)
	15	9	(5-14)	797	(399-1,595)	9171	(8373-9569)	23	(18-27)
CD vs UC (IgG)	Mixed	10	(8-12)	698		9270		22	(20-24)
	20	8	(5-11)	698	(399-997)	9270	(8971-9569)	24	(21-27)
	15	9	(5-14)	997	(598-1595)	8971	(8373-9370)	23	(18-27)
CD vs All symptomatic patients (IgA)	Mixed	5	(4-6)	299		9669		27	(26-28)
CD vs All symptomatic patients (IgA)	20	5	(3-8)	399	(100-1396)	9569	(8572-9868)	27	(24-29)
CD vs UC (IgA)	Mixed	4	(1-6)	199		9769		28	(26-31)
CD vs UC (IgA)	20	5	(3-7)	199	(100-399)	9769	(9569-9868)	27	(25-27)
CD vs All symptomatic patients (IgA and/or IgG)	Mixed	6	(3-9)	299		9669		26	(20-23)
CD vs All symptomatic patients (IgA and/or IgG)	20	7	(4-12)	698	(199-1994)	9270	(7974-9769)	25	(20-28)
CD vs UC (IgA and/or IgG)	Mixed	6	(1-11)	299		9669		26	(21-31)

Mixed diagnostic cut-off includes all cut-offs used as well as studies with unreported cut-offs. A prevalence of 322 per 100000 results in 32 patients with Crohn’s disease in this cohort. FN: False negatives; FP: False positives; TN: True negatives; TP: True positives; UC: Ulcerative colitis; Ig: Immunoglobulin.

Citation: Gkiouras K, Grammatikopoulou MG, Theodoridis X, Pagkalidou E, Chatzikyriakou E, Apostolidou AG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis. World J Gastroenterol 2020; 26(2): 246-265
URL: https://www.wjgnet.com/1007-9327/full/v26/i2/246.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i2.246